Phillip Frost

Phillip Frost News

  • Teva Returns to Roots after 'Nuthouse' Board Ousts CEO

    This time last year, the chairman and chief executive officer of Israel’s Teva Pharmaceutical Industries Ltd., the world’s biggest generic drugmaker, were foreigners. Miami billionaire Phillip Frost led the board and Jeremy Levin, a South African, was CEO. They were the first non- Israelis to hold those positions.

  • Billionaire Teva Chairman May Retire by Year’s End

    Teva Pharmaceutical Industries Ltd. Chairman Phillip Frost may retire before his board term ends next year if he can deliver on pledges to overhaul governance and find an adequate successor.

  • Frost’s Opko Plunges on Short Seller ‘Overvalued’ Call

    Opko Health Inc., the Tel Aviv- traded drug developer headed by billionaire Phillip Frost, tumbled the most in five years after short seller Lakewood Capital Management said the stock is “grossly overvalued.”

  • Teva’s Decline Fleeting to Bernstein Amid Board Fix

    Teva Pharmaceutical Industries Ltd. is set to rebound from the biggest weekly slump since November as a pledge to overhaul the Israeli company’s board offsets earnings growth concerns, Sanford C Bernstein & Co. said.

  • Teva Seen Struggling in CEO Search as Board Under Fire

    The shares of Teva Pharmaceutical Industries Ltd., the world’s largest generic-drug maker, have plunged 42 percent since their 2010 peak. Now the man hired to turn the company around just 18 months ago is gone, and analysts say it may be tough to find a replacement.

  • Teva Chairman Frost Backs Management Amid Criticism From Goldman

    Teva Pharmaceutical Industries Ltd. Chairman Phillip Frost said he backed the management’s strategy following criticism from Goldman Sachs Group Inc. and Morgan Stanley analysts who are advising investors to sell.

  • Teva Picks Vigodman as CEO Amid Restructuring Efforts

    Teva Pharmaceutical Industries Ltd. chose board member Erez Vigodman to run the world’s biggest generic-drug maker, seeking to revive earnings growth and the stock after the previous CEO left in a dispute with the board.

  • Teva’s Laquinimod MS Pill Fails to Win EU Agency Backing

    Teva Pharmaceutical Industries Ltd. failed to win backing from the European Union drug regulator for a new pill to treat multiple sclerosis, hurting the company’s effort to introduce a successor to its best-selling injection Copaxone.

  • Teva Calls Channel 2 Report on CEO-Chairman Feud Baseless

    Teva Pharmaceutical Industries Ltd. Chief Executive Officer Jeremy Levin denied a Channel 2 television report that he is considering resigning because of disagreements with Chairman Phillip Frost.

  • Teva Focused on Smaller M&A, Frost Says: Israel Overnight

    Teva Pharmaceutical Industries Ltd. is shifting away from the multi billion-dollar acquisitions that have defined its growth for the past decade, Chairman Phillip Frost said.

Sponsored Links
Curation software by Lingospot